Damora Therapeutics, Inc. (DMRA) stock
DMRANasdaqPharmaceutical PreparationsFiscal year ends December 31
$23.22−1.08 (-4.44%)
Close on Nov 20, 2026Market cap $1.44BP/E 5.8Yield 0.00%
Damora Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Damora Therapeutics's free cash flow for the twelve months ending Dec 31, 2022 was -$43.13M. For fiscal 2022 it was -$43.13M.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | -$43.13M | – |
| FY2021 | Dec 31, 2021 | -$52.53M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2022 | Dec 31, 2022 | -$11.49M | – |
| Q3 FY2022 | Sep 30, 2022 | -$9.99M | – |
| Q2 FY2022 | Jun 30, 2022 | -$14.81M | – |
| Q1 FY2022 | Mar 31, 2022 | -$6.84M | – |
| Q4 FY2021 | Dec 31, 2021 | -$17.83M | – |
| Q3 FY2021 | Sep 30, 2021 | -$9.21M | – |
| Q2 FY2021 | Jun 30, 2021 | -$11.28M | – |
| Q1 FY2021 | Mar 31, 2021 | -$14.22M | – |
See a number that looks wrong?